HomeNTRA • NASDAQ
add
Natera Inc
Previous close
$97.21
Day range
$95.38 - $98.17
Year range
$36.90 - $98.82
Market cap
11.88B USD
Avg Volume
1.16M
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
Market news
Financials
Income Statement
Revenue
Net income
(USD) | Dec 2023info | Y/Y change |
---|---|---|
Revenue | 311.10M | 43.20% |
Operating expense | 244.39M | 5.46% |
Net income | -78.03M | 45.27% |
Net profit margin | -25.08 | 61.79% |
Earnings per share | -0.64 | 53.28% |
EBITDA | -80.02M | 42.03% |
Effective tax rate | -0.25% | — |
Balance Sheet
Total assets
Total liabilities
(USD) | Dec 2023info | Y/Y change |
---|---|---|
Cash and short-term investments | 878.98M | -2.16% |
Total assets | 1.44B | 3.39% |
Total liabilities | 676.37M | -1.79% |
Total equity | 765.33M | — |
Shares outstanding | 120.76M | — |
Price to book | 15.19 | — |
Return on assets | -14.63% | — |
Return on capital | -17.36% | — |
Cash Flow
Net change in cash
(USD) | Dec 2023info | Y/Y change |
---|---|---|
Net income | -78.03M | 45.27% |
Cash from operations | -58.12M | 28.35% |
Cash from investing | 24.66M | 12.54% |
Cash from financing | 6.84M | -98.54% |
Net change in cash | -26.62M | -106.51% |
Free cash flow | -50.19M | 11.45% |
About
Natera, Inc. is a clinical genetic testing company based in Austin, Texas that specializes in non-invasive, cell-free DNA testing technology, with a focus on women’s health, cancer, and organ health. Natera’s proprietary technology combines novel molecular biology techniques with a suite of bioinformatics software that allows detection down to a single molecule in a tube of blood. Natera operates CAP-accredited laboratories certified under the Clinical Laboratory Improvement Amendments in San Carlos, California and Austin, Texas. Wikipedia
Founded
Jan 1, 2004
Headquarters
Website
Employees
3,288